No, Dr Murdoch was not there when the protocols were written and nor is he on record as saying the protocols were flawed either after a year in the job. If you are to rely on his time of elevation to the top job, then isn’t a year enough for him to come out and say there may be a problem here? Or was he sitting in the wheelhouse watching the approaching storm and failed to navigate around it, he is the Captain or was he paralysed by inaction? Let it just crash and start another one.
Dr Gavin however was the architect, and of course Dr Gavin would be bullish today on the call, he has to keep that hope as he has nowhere else to go, this is his career full stop, he will see his time out at POH over the next 3 years and then return to Monash imho.
What Dr Murdoch has already made a career from are these quotes and other motherhood statements in ‘blue sky mining’ during the last 15 years or so.
This paragraph in Quote 3 may sound familiar…
“the company continues to be engaged in very positive, dialogue with a number of other global pharmaceutical companies regarding future collaborations around our MPAC platform technology. The success of our most recent Phase II human trials has fuelled excitement in the possibility that the MPAC class can provide novel Alzheimer’s disease therapies. The potential for this class to provide therapeutics outside AD is also looking increasingly promising.”
Let’s see now, where did we hear that last?
Quote 1 Shire's Specialty Pharmaceuticals Senior Vice President, Hematology, Ross Murdoch says: "There remains a significant unmet need for a once-a-day, oral iron chelator in a convenient dosage form for the treatment of transfusional iron overload with a better safety profile than currently available treatments(2). We believe FBS0701 has the potential to meet that need. We hope to use our expertise in hematology coupled with our proven ability to progress products through the development pipeline to bring FBS0701 to the global marketplace.
This acquisition marks an important step for Shire in building a business that serves the growing needs of specialty hematologists and their patients."
Quote 2 Prana has been pleased with the PBT-1 side effect profile in its trial. “It is all a matter of dose, and though clioquinol was taken off the market decades ago, it was originally used at very high doses,” explains Dr. Murdoch. “For Alzheimer's disease, we have reduced that dose.” “Our intention is that those compounds will not only be tested for their efficacy in AD, but they will also be optimized for other diseases, such as Parkinson's,” says Dr. Murdoch.
Quote 3
Dr. Ross Murdoch, Prana`s Chief Operating Officer, said, "Through Prana’s efforts in the area of neurological diseases we have identified multiple potential diagnostic and therapeutic targets which we believe worthy of exploration. Our commitment is to continually strengthen the technological base of the company through in-house and collaborative research; increasing the possibility of success and in turn lessening our reliance on any single technology. This collaboration with Schering A.G. is inline with our commitment and will allow funding of additional exciting technologies that although separate, complement our existing premier platform technology based on the Metal Protein Attenuating Compound ("MPAC") class of compounds. This collaboration will expand Prana’s project areas bringing significant additional funding and scientific expertise into the company’s laboratories.”
“Dr. Murdoch continued, “the company continues to be engaged in very positive, dialogue with a number of other global pharmaceutical companies regarding future collaborations around our MPAC platform technology. The success of our most recent Phase II human trials has fuelled excitement in the possibility that the MPAC class can provide novel Alzheimer’s disease therapies. The potential for this class to provide therapeutics outside AD is also looking increasingly promising.”
BSW
POH Price at posting:
0.8¢ Sentiment: None Disclosure: Held
(20min delay)